Abstract
Background Irrespective of neurodegeneration, the decline of olfactory function might also reflect a wider range of pathological conditions contributing to mortality. However, the potential explanations and their predictive values have rarely been reported.
Methods A total of 1,433 older adults aged ≥ 60 years without neurodegenerative disease were administered a follow-up of 8.6 years on average. Sniffin’ Sticks Screening Test was used to assess the olfactory identification at baseline. Survival status during the follow-up was obtained from the local Center for Disease Control and Prevention. Bidirectional stepwise Cox proportional hazards regression was used to identify variables associated with mortality. Two predictive models were constructed by statistical learning methods.
Results All-cause mortality rate was 1.1/100 person-years during the follow-up. Sex (HR = 0.65, 95%CI 0.46 - 0.93), age (HR = 1.12, 95%CI 1.10 - 1.15), chronic kidney disease (HR = 1.88, 95%CI 1.09 - 3.25), low density lipoprotein (HR = 0.81, 95%CI 0.67 - 0.99), anemia (HR = 2.74, 95%CI 1.19 - 6.30), and fail to identify coffee odor (HR = 1.96, 95%CI 1.19 - 3.23) were significantly associated with all-cause mortality. The logistic regression and the random forest predictive models showed similar predictive accuracy (0.91 and 0.90) and area under the receiver operating characteristic curve (0.77 and 0.75).
Conclusions The association between poor olfactory and long-term mortality was verified among Chinese older population. Certain odors identification ability may contribute to the prediction of long-term mortality along with other important risk factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants of Shanghai Municipal Science and Technology Major Project (2018SHZDZX01) and ZJLab, National Natural Science Foundation of China (81773513, 82071200), Scientific Research Plan Project of Shanghai Science and Technology Committee (17411950701, 17411950106), and National Project of Chronic Disease (2016YFC1306402).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Medical Ethical Committee of Huashan Hospital, Fudan University, Shanghai, China (approval number: 2009-195). All participants and/or their legal guardians have signed written informed consent for participation in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used during the study are available from the corresponding author by reasonable request.
